Home Featured Page 104

Featured

Latest

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Analysis: Patent Applications Provide Hints at Terran Biosciences’ Strategy

PT427 – The Philosophy of Law Enforcement, The Criminalization of Self-Directed...

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment...

MIND CURE ANNOUNCES LNG ENERGY GROUP CREDIT AGREEMENT IN THE AMOUNT...

Small Pharma Reports Fiscal First Quarter 2024 Highlights

Optimi Health Announces Receipt of Purported Termination Notice

Navigating Psychedelics: Vital Tools for Risk Reduction and Integration – Denver

Kiyumí Psilocybin Retreat & Vital Training: Netherlands

Prasada Transpersonal Breathwork Retreat: Portugal

Atman Psychedelic Retreat & Vital Training: Jamaica 2

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Analysis: Patent Applications Provide Hints at Terran Biosciences’ Strategy

PT427 – The Philosophy of Law Enforcement, The Criminalization of Self-Directed...

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment...

MIND CURE ANNOUNCES LNG ENERGY GROUP CREDIT AGREEMENT IN THE AMOUNT...

Small Pharma Reports Fiscal First Quarter 2024 Highlights

Optimi Health Announces Receipt of Purported Termination Notice

Navigating Psychedelics: Vital Tools for Risk Reduction and Integration – Denver

Kiyumí Psilocybin Retreat & Vital Training: Netherlands

Prasada Transpersonal Breathwork Retreat: Portugal

Atman Psychedelic Retreat & Vital Training: Jamaica 2

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY